Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 756 participants.
Also called NCT01652872
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 756 participants
- Sponsor
- Registry
-
NCT01652872
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01652872. Randomized; triple masking; primary purpose treatment. Start 2012-07-30 (actual); primary completion 2017-10-19 (actual). Results posted on 2018-11-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
- Acronym
- START-CKD
- Condition
- Anemia in Chronic Kidney Disease Patients Not on Dialysis
- Intervention (Biological)
- Darbepoetin alfa
- Intervention (Other)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01652872- Content hash
8453183b1b89a5e35dca86a1217d56888b47a06498b9217987d384e6f3feb74e